Key takeaways
- The UHMS Hyperbaric Medicine Indications Manual 15th Edition was released by Best Publishing in 2023 (ISBN 978-1-947239-42-5).
- The 15th Edition adds a dedicated new chapter on Dosing of Hyperbaric Oxygen — the first time dosing is treated as a standalone editorial topic.
- A new approved indication added by the Oxygen Therapy Committee is included (building on the sudden sensorineural hearing loss addition from the 14th Edition).
- CMS Medicare coverage continues to track the UHMS indication list via LCD L35021 — so UHMS additions typically translate to US reimbursement.
- The manual remains the authoritative US clinical reference for which conditions are considered standard-of-care HBOT vs. research-stage vs. investigational.
Why the UHMS list is the anchor
In the US, the Undersea and Hyperbaric Medical Society is the clinical authority for hyperbaric medicine. UHMS maintains the list of medical indications for which HBOT is considered standard of care — currently 14 approved conditions as of the 15th Edition. CMS Medicare reimbursement (LCD L35021) follows this list, FDA chamber clearances are tied to it, and most US private insurers mirror CMS coverage. The practical consequence: if an indication is on the UHMS list, it is covered clinical HBOT; if not, it is off-label and generally cash-pay.
What the 15th Edition changed
The 15th Edition of the Hyperbaric Medicine Indications Manual was released by Best Publishing in 2023, with ISBN 978-1-947239-42-5. The headline changes:
1. A new dedicated Dosing chapter
For the first time, HBOT dosing is treated as a standalone editorial topic. Prior editions discussed dose implicitly within each indication chapter — the 15th formalises guidance on treatment pressure (ATA), session duration, number of sessions, and total course length. This brings HBOT dose language closer to the structured dose-response framework used in pharmacology.
Practical consequence: clinicians, facility administrators, and reviewers now have a canonical reference for what constitutes an adequate HBOT course for each indication, rather than reasoning case-by-case.
2. New indication added
The 15th Edition includes a new indication approved by the UHMS Oxygen Therapy Committee. This continues the pattern of incremental additions — the 14th Edition added sudden sensorineural hearing loss (SSNHL), which CMS brought under Medicare coverage in 2021.
3. Chapter updates across existing indications
Existing chapters covering air/gas embolism, central retinal artery occlusion, carbon monoxide poisoning, clostridial myonecrosis, acute traumatic ischemias, decompression sickness, delayed radiation injuries, SSNHL, intracranial abscess, and necrotising soft tissue infections were updated to reflect newer evidence and guideline revisions.
What did NOT change
Several widely-discussed off-label indications are still not UHMS-approved as of the 15th Edition:
- Traumatic brain injury (TBI) — despite growing Efrati Lab RCT evidence
- Stroke recovery (chronic phase)
- Long COVID / PASC
- Fibromyalgia
- PTSD
- Autism spectrum disorder
- Anti-aging / longevity
These remain Tier 2 (research-stage) or Tier 3 (investigational) in UHMS evidence framework. HBOT for these indications is off-label in the US and typically cash-pay. UHMS review of several of these — particularly TBI and long COVID — is actively anticipated as the RCT evidence base grows.
Why dosing matters more than you'd think
The addition of a Dosing chapter is quietly significant. For years, HBOT trial failures have been scrutinised for dose confounds — most famously the DoD HOPPS and BRIMS TBI trials, where sham arms delivering ~1.3 ATA may themselves have been active (positive) at a sub-therapeutic dose, masking a true HBOT vs. placebo contrast.
A formal UHMS dosing framework helps future trial designers avoid these confounds and gives clinicians a defensible answer when asked "how many sessions is enough?" The answer has always varied by indication — 3 for acute CO poisoning, 20-40 for wound care, 40-60 for the Efrati Lab neurological protocol — but was scattered across indication chapters and primary literature.
What it means for patients and clinicians
For patients considering HBOT: the UHMS list defines what is covered standard-of-care. The 15th Edition does not meaningfully change the covered-indication landscape, but it does strengthen the dosing framework, which is important if you are evaluating whether a specific clinic is proposing an evidence-aligned course.
For clinicians: the Dosing chapter is a useful reference when writing orders or justifying authorisation requests. The chapter updates on existing indications may incorporate newer meta-analyses and should be cross-referenced for current wound care, radiation injury, and SSNHL protocols.
What to watch next
The anticipated next inflection points for the UHMS list are (1) formal review of long COVID HBOT evidence following the Zilberman-Itskovich RCTs and growing registry data, (2) revisiting TBI evidence with newer Efrati Lab and Harch work, and (3) any CMS LCD updates reflecting the 15th Edition changes. The 16th Edition is years away but these interim reviews are where coverage expansion typically originates.
Frequently Asked Questions
Why does the UHMS list matter?
US Medicare (CMS) reimbursement follows the UHMS indication list via LCD L35021. FDA chamber clearances are tied to it. Private insurers typically mirror CMS. The UHMS list is the practical boundary between covered clinical HBOT and off-label HBOT.
How often is the list updated?
The full Indications Manual is updated every few years (14th Edition 2019, 15th Edition 2023). Individual indications can be modified or added between editions through formal UHMS review by the Oxygen Therapy Committee.
What is the new "Dosing" chapter about?
The 15th Edition formalises guidance on treatment pressure (ATA), session duration, number of sessions, and course length — bringing HBOT dosing closer to the structured dose-response framework of other medical therapies.
Did TBI or long COVID get added?
Neither has been added to the UHMS approved list as of the 15th Edition. Both remain research-stage with growing but incomplete evidence. A UHMS review of neurological HBOT indications is widely anticipated.
